|
Volumn 126, Issue 6, 2005, Pages 419-425
|
Pharmacological and clinical profile of humanized anti-human IL-6 receptor antibody (tocilizumab, ACTEMPA®), a novel therapeutic drug for Castleman's disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ATLIZUMAB;
INTERLEUKIN 6;
INTERLEUKIN 6 RECEPTOR;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA;
DRUG MECHANISM;
REVIEW;
ANIMAL;
BINDING COMPETITION;
CELL PROLIFERATION;
CLINICAL TRIAL;
CYTOLOGY;
DRUG DESIGN;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
LYMPH NODE;
METABOLISM;
PATHOLOGY;
PHYSIOLOGY;
SIGNAL TRANSDUCTION;
ANIMALS;
ANTIBODIES, MONOCLONAL;
BINDING, COMPETITIVE;
CELL PROLIFERATION;
CLINICAL TRIALS;
DRUG DESIGN;
GIANT LYMPH NODE HYPERPLASIA;
HUMANS;
INTERLEUKIN-6;
LYMPH NODES;
RECEPTORS, INTERLEUKIN-6;
RECOMBINANT PROTEINS;
SIGNAL TRANSDUCTION;
|
EID: 33644934001
PISSN: 00155691
EISSN: 13478397
Source Type: Journal
DOI: 10.1254/fpj.126.419 Document Type: Review |
Times cited : (5)
|
References (32)
|